Haleon PLC Sponsored ADR

HLN Healthcare Drug Manufacturers Specialty & Generic

Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.

9.13 0.10 −1.08%
Market cap
$40.2B
P/E
20.5×
Fwd P/E
16.5×
Dividend yield
2.16%
F-score
8/9
Altman Z
3.04
Beneish M
−2.60
Dividend safety
63/100

Haleon PLC Sponsored ADR (HLN) EBITDA

Alert me on EBITDA

Haleon PLC Sponsored ADR's EBITDA for fiscal 2025 was $3.7B, up 13.1% from $3.2B in fiscal 2024. Over the past ten years it has ranged from $2.6B (fiscal 2022) to $3.7B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. Haleon PLC Sponsored ADR ranks 2nd of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 $3.7B 13.06%
FY2024 $3.2B 12.76%
FY2023 $2.9B 9.76%
FY2022 $2.6B (12.96%)
FY2021 $3.0B 3.54%
FY2020 $2.9B 10.65%
FY2019 $2.6B —

Quarterly newest first

Period EBITDA Change
Sep 2024 $916.9M 10.39%
Mar 2024 $830.6M 12.35%
Sep 2023 $739.3M (58.13%)
Jun 2023 $1.8B 131.83%
1 more quarters

Against its own ten years

Low $2.6B High $3.7B
Ten-year median $2.9B
Current reading's percentile 100

EBITDA against peers

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on HLN